Welcome to our dedicated page for KAIROS PHARMA SEC filings (Ticker: KAPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kairos Pharma, Ltd. (KAPA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on the NYSE American. These documents offer detailed information on its oncology programs, licensing arrangements, and corporate governance, and are an important resource for understanding how Kairos Pharma reports its activities to regulators and investors.
Through current reports on Form 8-K, Kairos Pharma has disclosed items such as equity compensation decisions, including grants of restricted stock units (RSUs) and cash bonuses to executives and directors under its equity incentive plan. These filings describe vesting terms, valuation references, and potential accelerated vesting upon a change in control, giving insight into the company’s approach to executive and board compensation.
Other 8-K filings outline material agreements and intellectual property arrangements. For example, Kairos Pharma has reported novation agreements that transferred exclusive license rights from its subsidiary Enviro Therapeutics, Inc. to the listed company, including licenses covering compositions and methods for treating diseases and conditions by depletion or detection of mitochondrial or genomic DNA from circulation and sensitization of tumors to therapies through endoglin (CD105) antagonism. A separate novation agreement with Tracon Pharmaceuticals, Inc. transferred Enviro’s rights and obligations under a license and supply agreement for TRC105 and CD105 technologies to Kairos.
Kairos Pharma also uses Form 8-K to furnish press releases and slide presentations related to its clinical programs, such as interim safety and efficacy data from the Phase 2 ENV105 trial in metastatic castration-resistant prostate cancer and initial Phase 1 data in non-small cell lung cancer. While these exhibits are furnished rather than filed for certain purposes, they provide additional context on the company’s CD105-targeted strategy and clinical development plans.
On Stock Titan, investors can view these filings as they are pulled from the SEC’s EDGAR system and use AI-powered summaries to interpret key points. The platform highlights major elements of Kairos Pharma’s disclosures, including clinical trial updates, licensing arrangements, compensation decisions, and other reported events, helping users navigate the technical language and understand how each filing relates to the company’s oncology pipeline and corporate structure.